Y Teraki, S Tanaka, K Hitomi, S Izaki. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Antibodies, Monoclonal/adverse effectsArthritis, Rheumatoid/drug therapyCD4-Positive T-Lymphocytes/metabolismCD8-Positive T-Lymphocytes/metabolismDermatologic Agents/adverse effectsDrug EruptionsFemaleFlow CytometryHumansInfliximabInterleukin-17/bloodInterleukins/bloodMiddle AgedPhenotypePsoriasis/chemically inducedPsoriasis/immunologyPsoriasis/pathologyReceptors, Lymphocyte Homing/immunologyTh17 Cells/metabolismTumor Necrosis Factor-alpha/antagonists & inhibitors
Substances: See more » Antibodies, MonoclonalDermatologic AgentsInterleukin-17InterleukinsReceptors, Lymphocyte HomingTumor Necrosis Factor-alphaInfliximabinterleukin-22
Year: 2010 PMID: 20731653 DOI: 10.1111/j.1365-2133.2010.10002.x
Source DB: PubMed Journal: Br J Dermatol ISSN: 0007-0963 Impact factor: 9.302